[
  {
    "ts": null,
    "headline": "Eli Lilly's Most Promising Weight Loss Drug May Come With a Surprising Benefit: Pain Relief",
    "summary": "Retatrutide is an exciting GLP-1 drug that has explosive potential.",
    "url": "https://finnhub.io/api/news?id=5a9d64361866295160bd6dd4db71875d7965656acba2d9477653c08ff942f2b4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768419300,
      "headline": "Eli Lilly's Most Promising Weight Loss Drug May Come With a Surprising Benefit: Pain Relief",
      "id": 138114633,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Retatrutide is an exciting GLP-1 drug that has explosive potential.",
      "url": "https://finnhub.io/api/news?id=5a9d64361866295160bd6dd4db71875d7965656acba2d9477653c08ff942f2b4"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk to Keep Pursuing Deals to Expand Obesity Portfolio, CEO Says",
    "summary": "Novo Nordisk (NVO) will keep looking for deals to expand its obesity portfolio, CEO Mike Doustdar sa",
    "url": "https://finnhub.io/api/news?id=90045974086448633d66b1fa96d7070c4a4a35e15959e4f8bda318cbeb417af6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768417947,
      "headline": "Novo Nordisk to Keep Pursuing Deals to Expand Obesity Portfolio, CEO Says",
      "id": 138114634,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Novo Nordisk (NVO) will keep looking for deals to expand its obesity portfolio, CEO Mike Doustdar sa",
      "url": "https://finnhub.io/api/news?id=90045974086448633d66b1fa96d7070c4a4a35e15959e4f8bda318cbeb417af6"
    }
  },
  {
    "ts": null,
    "headline": "Why Eli Lilly Stock Gained 39.2% In 2025",
    "summary": "The company is benefiting mightily from its portfolio of weight-loss drugs.",
    "url": "https://finnhub.io/api/news?id=4180c8fcca91c67e8391801f306279ae1793b69dee29504edbc007fd47ed47cd",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768415638,
      "headline": "Why Eli Lilly Stock Gained 39.2% In 2025",
      "id": 138114635,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The company is benefiting mightily from its portfolio of weight-loss drugs.",
      "url": "https://finnhub.io/api/news?id=4180c8fcca91c67e8391801f306279ae1793b69dee29504edbc007fd47ed47cd"
    }
  },
  {
    "ts": null,
    "headline": "The Bull Case For Revvity (RVTY) Could Change Following Upbeat 2025 Guidance And New Lilly AI Alliance",
    "summary": "In recent days, Revvity, Inc. updated its outlook for the fourth quarter and full year 2025, guiding to approximately US$772,000,000 in Q4 revenue and about US$2.86 billion for the year, while indicating adjusted earnings per share should exceed its prior guidance range. A separate announcement revealed that Revvity and Eli Lilly are jointly expanding access to Lilly’s TuneLab AI models through Revvity’s Signals platform, underscoring Revvity’s push to embed advanced AI and federated...",
    "url": "https://finnhub.io/api/news?id=2376c6082f140bbbbe0af7f75a2ee7e9b1fb64107678299a03f81c3dcb830938",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768410968,
      "headline": "The Bull Case For Revvity (RVTY) Could Change Following Upbeat 2025 Guidance And New Lilly AI Alliance",
      "id": 138113126,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "In recent days, Revvity, Inc. updated its outlook for the fourth quarter and full year 2025, guiding to approximately US$772,000,000 in Q4 revenue and about US$2.86 billion for the year, while indicating adjusted earnings per share should exceed its prior guidance range. A separate announcement revealed that Revvity and Eli Lilly are jointly expanding access to Lilly’s TuneLab AI models through Revvity’s Signals platform, underscoring Revvity’s push to embed advanced AI and federated...",
      "url": "https://finnhub.io/api/news?id=2376c6082f140bbbbe0af7f75a2ee7e9b1fb64107678299a03f81c3dcb830938"
    }
  },
  {
    "ts": null,
    "headline": "Prediction: These Could Be the Best-Performing Healthcare Stocks Through 2030",
    "summary": "Plenty of growth lies ahead for these top healthcare companies.",
    "url": "https://finnhub.io/api/news?id=e266373e359aea889ea5c28e708eccdc34df4111e5d2e9d1880f1eefc76c954b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768408500,
      "headline": "Prediction: These Could Be the Best-Performing Healthcare Stocks Through 2030",
      "id": 138113127,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Plenty of growth lies ahead for these top healthcare companies.",
      "url": "https://finnhub.io/api/news?id=e266373e359aea889ea5c28e708eccdc34df4111e5d2e9d1880f1eefc76c954b"
    }
  },
  {
    "ts": null,
    "headline": "MoneyShow's Best Investment Ideas For 2026: Part 4",
    "summary": "MoneyShow presents top investment ideas for 2026 from leading advisors. Part 4 includes Eli Lilly, Enterprise Products Partners, Federal Agricultural Mortgage Corp. and GE Vernova.",
    "url": "https://finnhub.io/api/news?id=65c74d9b41f60e7016f7d24a5a760ab8b93ca3d17676b85ff4d49b9e6c5818c9",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768405800,
      "headline": "MoneyShow's Best Investment Ideas For 2026: Part 4",
      "id": 138115231,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1198436238/image_1198436238.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "MoneyShow presents top investment ideas for 2026 from leading advisors. Part 4 includes Eli Lilly, Enterprise Products Partners, Federal Agricultural Mortgage Corp. and GE Vernova.",
      "url": "https://finnhub.io/api/news?id=65c74d9b41f60e7016f7d24a5a760ab8b93ca3d17676b85ff4d49b9e6c5818c9"
    }
  },
  {
    "ts": null,
    "headline": "Here's Why Eli Lilly (LLY) is a Strong Momentum Stock",
    "summary": "The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.",
    "url": "https://finnhub.io/api/news?id=1c61526110006acf3b4b34138ecc0cdcd349ceef86326cf33556bfe9b601d9eb",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768402204,
      "headline": "Here's Why Eli Lilly (LLY) is a Strong Momentum Stock",
      "id": 138113128,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.",
      "url": "https://finnhub.io/api/news?id=1c61526110006acf3b4b34138ecc0cdcd349ceef86326cf33556bfe9b601d9eb"
    }
  },
  {
    "ts": null,
    "headline": "Ontario Pioneers Access to Treatment for Severe Alopecia Areata with Lilly's Olumiant®",
    "summary": "Eli Lilly Canada Inc. (\"Lilly\") announced today that Ontario leads the way as the first province to add Olumiant® for severe alopecia areata to its public drug formulary—the first and only treatment for adult patients with severe alopecia areata available through public coverage.",
    "url": "https://finnhub.io/api/news?id=90512b601d8e3acbd557955829e8b65910a2fa01f82a9b453446cf560c45a2ad",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768399200,
      "headline": "Ontario Pioneers Access to Treatment for Severe Alopecia Areata with Lilly's Olumiant®",
      "id": 138111868,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly Canada Inc. (\"Lilly\") announced today that Ontario leads the way as the first province to add Olumiant® for severe alopecia areata to its public drug formulary—the first and only treatment for adult patients with severe alopecia areata available through public coverage.",
      "url": "https://finnhub.io/api/news?id=90512b601d8e3acbd557955829e8b65910a2fa01f82a9b453446cf560c45a2ad"
    }
  },
  {
    "ts": null,
    "headline": "Is It Time to Dump Your Shares of Eli Lilly?",
    "summary": "What happens with Eli Lilly's GLP-1 shot now that Novo Nordisk has come out with a GLP-1 pill?",
    "url": "https://finnhub.io/api/news?id=e80a72fa51236ca3be3c8cd4eb49a1b377e560d1bd6dad00b6a5b55e01de5700",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768398720,
      "headline": "Is It Time to Dump Your Shares of Eli Lilly?",
      "id": 138111146,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "What happens with Eli Lilly's GLP-1 shot now that Novo Nordisk has come out with a GLP-1 pill?",
      "url": "https://finnhub.io/api/news?id=e80a72fa51236ca3be3c8cd4eb49a1b377e560d1bd6dad00b6a5b55e01de5700"
    }
  },
  {
    "ts": null,
    "headline": "Nvidia Eyes First Breakout Of 2026. These Clues — And An Innovative Deal With Eli Lilly — Bode Well.",
    "summary": "Now set to collaborate with Eli Lilly to develop drugs in the AI era, Nvidia looks to trigger a new climb.",
    "url": "https://finnhub.io/api/news?id=687166d61b0e60430496c73a49cb231931b59385bb21a0290f6794676ff468ae",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768395620,
      "headline": "Nvidia Eyes First Breakout Of 2026. These Clues — And An Innovative Deal With Eli Lilly — Bode Well.",
      "id": 138111000,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Now set to collaborate with Eli Lilly to develop drugs in the AI era, Nvidia looks to trigger a new climb.",
      "url": "https://finnhub.io/api/news?id=687166d61b0e60430496c73a49cb231931b59385bb21a0290f6794676ff468ae"
    }
  },
  {
    "ts": null,
    "headline": "PFE Market Cap Falls More Than $7B in a Month: How to Play the Stock",
    "summary": "Pfizer shares fall nearly 5% in a month after weak 2026 guidance, sparking debate over buying the dip or staying cautious.",
    "url": "https://finnhub.io/api/news?id=f561be1dda255d356534a72334da790ad6b8f583336ccbaf7307d1e2ecf6aaca",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768394700,
      "headline": "PFE Market Cap Falls More Than $7B in a Month: How to Play the Stock",
      "id": 138111148,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Pfizer shares fall nearly 5% in a month after weak 2026 guidance, sparking debate over buying the dip or staying cautious.",
      "url": "https://finnhub.io/api/news?id=f561be1dda255d356534a72334da790ad6b8f583336ccbaf7307d1e2ecf6aaca"
    }
  },
  {
    "ts": null,
    "headline": "Healthy Returns: Novo Nordisk CEO on GLP-1 pricing, and more insights from the JPM conference",
    "summary": "Novo Nordisk's CEO spoke about GLP-1 pricing and Pfizer's CEO spoke about the company's obesity ambitions while at the JPMorgan Healthcare Conference.",
    "url": "https://finnhub.io/api/news?id=d6f8d00d213e88039b110411652e19cc7093e8ec9df7d4de80999607d7c8eb25",
    "source": "CNBC",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768392531,
      "headline": "Healthy Returns: Novo Nordisk CEO on GLP-1 pricing, and more insights from the JPM conference",
      "id": 138112555,
      "image": "https://image.cnbcfm.com/api/v1/image/108222573-17624550972025-11-06t184628z_1673660215_rc25rhas1dn5_rtrmadp_0_usa-trump.jpeg?v=1762455130&w=1920&h=1080",
      "related": "LLY",
      "source": "CNBC",
      "summary": "Novo Nordisk's CEO spoke about GLP-1 pricing and Pfizer's CEO spoke about the company's obesity ambitions while at the JPMorgan Healthcare Conference.",
      "url": "https://finnhub.io/api/news?id=d6f8d00d213e88039b110411652e19cc7093e8ec9df7d4de80999607d7c8eb25"
    }
  },
  {
    "ts": null,
    "headline": "Lilly, chasing Novo, expects second-quarter FDA decision on obesity pill",
    "summary": "Speaking at the J.P. Morgan conference, CEO David Ricks said he anticipates a “rapid review” for orforglipron that's currently speeding along “at pace.”",
    "url": "https://finnhub.io/api/news?id=34807c20a41ea3c8366eb4968a1f1e6bfabb555e11a79863ee281ab6dcb59940",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768391460,
      "headline": "Lilly, chasing Novo, expects second-quarter FDA decision on obesity pill",
      "id": 138113129,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Speaking at the J.P. Morgan conference, CEO David Ricks said he anticipates a “rapid review” for orforglipron that's currently speeding along “at pace.”",
      "url": "https://finnhub.io/api/news?id=34807c20a41ea3c8366eb4968a1f1e6bfabb555e11a79863ee281ab6dcb59940"
    }
  },
  {
    "ts": null,
    "headline": "Crispr Therapeutics: Patience And Opportunity Through Volatility",
    "summary": "CRISPR Therapeutics analysis: long-term upside despite volatility. Track Casgevy ramp, pipeline milestones & cash runway.",
    "url": "https://finnhub.io/api/news?id=89047c96a595659788a2b7bb70ab59e059bef0b6f8f6f62953a86e33fab86f5b",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768390208,
      "headline": "Crispr Therapeutics: Patience And Opportunity Through Volatility",
      "id": 138112347,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2180173390/image_2180173390.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "CRISPR Therapeutics analysis: long-term upside despite volatility. Track Casgevy ramp, pipeline milestones & cash runway.",
      "url": "https://finnhub.io/api/news?id=89047c96a595659788a2b7bb70ab59e059bef0b6f8f6f62953a86e33fab86f5b"
    }
  },
  {
    "ts": null,
    "headline": "Lilly, Novo test direct-to-employer approach that could cut out PBMs and lower costs",
    "summary": "The GLP-1 giants are the first to try out this new model, but more companies may follow.",
    "url": "https://finnhub.io/api/news?id=0e41a60a8426f0ea84c8cef67a1b7a5986c0f7be3557b2ce08e18171f4421405",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768376230,
      "headline": "Lilly, Novo test direct-to-employer approach that could cut out PBMs and lower costs",
      "id": 138111149,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The GLP-1 giants are the first to try out this new model, but more companies may follow.",
      "url": "https://finnhub.io/api/news?id=0e41a60a8426f0ea84c8cef67a1b7a5986c0f7be3557b2ce08e18171f4421405"
    }
  }
]